Results 221 to 230 of about 2,463,634 (361)

Integration of patient-reported outcome measures with key clinical outcomes after immediate latissimus dorsi breast reconstruction and adjuvant treatment [PDF]

, 2012
Zoë Winters, Joanne Haviland, V Balta, John R. Benson, Alexander M. Reece-Smith, Nadine Betambeau   +5 more
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

If patient‐reported outcome measures are considered key health‐care quality indicators, who is excluded from participation? [PDF]

, 2012
Thilo Kroll, Sally Wyke, Deepa Jahagirdar, Karen Ritchie   +3 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

PIH64 A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOMES MEASURE OF ATTITUDES TOWARD COMPLEMENTARY AND ALTERNATIVE MEDICINE IN MENOPAUSE

, 2010
S Bunsiriluck, Evan Williamson, Parastou Donyai   +2 more
openalex   +1 more source

Validation of the Patient-Reported Outcome Measures Tool "Catquest" in Odia Language. [PDF]

Cureus
Sen S, Das M, Ak K, Mohanty A, Goel A.
europepmc   +1 more source

Chronic rhinosinusitis, what do patient-reported outcome measures measure? [PDF]

, 2023
Dietz de Loos, D.A.E.
core  

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

PIH15 SENSITIVITY OF GENERIC PATIENT-REPORTED OUTCOMES MEASURES AMONG CAREGIVERS OF CHILDREN WITH CRANIOFACIAL MALFORMATION

, 2010
Nalin Payakachat, SD Grosse, J. M. Tilford   +2 more
openalex   +1 more source

TOUCH® Patient Reported Outcomes Study: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients [PDF]

, 2012
Sunanda V. Kane, Arpita Nag, Lori Taylor, Gary S. Hogge, Jean–Frédéric Colombel, James H. Lewis, David T. Rubin, Remo Panaccione   +7 more
openalex   +1 more source